Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Jan 31, 2023 | Interviews

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug Celine Castronuovo | Bloomberg Law News “More than 1.4 million patients have used Humira globally, according to AbbVie. The drug takes up a huge chunk of Medicare spending in the US, with an HHS...

New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets

Jan 26, 2023 | Analysis

New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.” This report, authored by Alex Brill...

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition

Aug 25, 2022 | Interviews

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat down with CAPD spokesperson Maura Keefe to...

New PCMA Podcast Highlights Importance of Prescription Drug Rebates

Aug 16, 2022 | Press Releases

New PCMA Podcast Highlights Importance of Prescription Drug Rebates PCMA released the following press release regarding Alex Brill’s interview on the importance of prescription drug rebates. (Washington, D.C.) — The Pharmaceutical Care Management Association’s...

Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded

May 12, 2022 | Analysis

Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded MGA’s Alex Brill submitted a letter in response to a request for information from the Federal Trade Commission. The FTC was looking for information regarding the business practices of pharmacy benefit...